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mutations. Direct sequencing revealed BRCA1 G2508T
as a nonsense mutation resulting in Glurstop codon and
BRCA2 3295insA as an in-frame stop codon at position
1025. Mutation results were confirmed at a separate
BRCA1 and BRCA2 testing facility in Toronto. These
are novel mutations not previously reported in the Breast
Cancer Information Core database.
This patient had a maternal and paternal history of
breast cancer. The maternal side contained cases of post-
menopausal breast cancer: her mother (patient 6) was
diagnosed with bilateral breast cancer at ages 70 and
75 years, and her aunt (patient 5) was diagnosed at ages
68 and 72 years; her grandmother (patient 2) was di-
agnosed with breast cancer at age 72 years. The paternal
side contained cases of premenopausal breast cancer: a
cousin once removed (patient 35) was diagnosed with
breast cancer at age 33 years, her grandmother (patient
20) was diagnosed at age 75 years, and a distant cousin
(patient 59) was diagnosed at age 35 years. Interestingly,
her mother did not have either mutation, suggesting that
both BRCA1 and BRCA2 germ-line mutations origi-
nated from the father of the proband. This is consistent
with the ages at onset of the women on the paternal
side, indicating the presence of at least one of these mu-
tations in the women diagnosed with premenopausal
breast cancer. To date, no other family members are
available for testing. For counseling of individuals iden-
tified as double heterozygotes for mutations in BRCA1
and BRCA2, the risk of transmitting a breast can-
cer–susceptibility gene(s) to any offspring is 3/4.
The frequency of BRCA1 and BRCA2 mutations in
the United Kingdom and Canada has been estimated at
1/850–1/500 individuals (Easton 1993; Ford et al.
1995); therefore, the likelihood of finding a double het-
erozygote in this population is between 1/700,000 and
1/250,000. It is estimated that, for individuals of Ash-
kenazi Jewish descent, the likelihood of being a carrier
for one of three common BRCA1 or BRCA2 mutations
is x1/50 (Roa 1996; Tonin et al. 1996); therefore, the
likelihood of finding a double or compound heterozy-
gote is ∼1/2,500 for Ashkenazi Jewish families unse-
lected for cancer.
This individual is the first example to date of a double
heterozygote for the high-penetrance breast can-
cer–susceptibility genes, BRCA1 and BRCA2, outside of
the Ashkenazi Jewish population (Ramus et al. 1997).
This finding is predictably rare, with a maximum fre-
quency of 1/250,000. Our patient was diagnosed with
early-onset breast cancer at age 35 years, an age typical
of other BRCA1/BRCA2–associated breast cancers. Her
case does not suggest a more severe presentation or
younger age at diagnosis for women found to harbor
germ-line mutations in both genes. We cannot generalize
that complete screening of BRCA1 and BRCA2 in fam-
ilies with a previously identified mutation in either gene
is necessary until other double heterozygotes are iden-
tified. However, if the family mutation is not found in
women diagnosed with early-onset breast cancer or
ovarian cancer, there is a basis for comprehensive screen-
ing of both genes.
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Evidence of Founder Mutations in Finnish BRCA1 and
BRCA2 Families
To the Editor:
Approximately 4%–10% of breast and ovarian cancer
is thought to be inherited (Newman et al. 1988). Most
hereditary ovarian cancer cases and a significant portion
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Table 1
Classification of 88 Cancer Families According to Occurrence of
Breast and Ovarian Cancer in 1st-Degree Relatives
NO. OF CASES OF
BREAST CANCER
NO. OF FAMILIES IN WHICH NO. OF CASES
OF OVARIAN CANCER 
0 1 2 3 4
0 1 2 1 1
1 13 9 2
2 27 5 1
3 14 1
4 8
5 1 1 1
of breast cancer cases are due to mutations in the BRCA1
gene (Miki et al. 1994). In addition, BRCA2 mutations
account for a large fraction of hereditary breast cancer
but for only a small number of cases of hereditary ovar-
ian cancer (Wooster et al. 1995). Other cancer pheno-
types associated with mutations in these genes are pros-
tate cancer and colon carcinoma, for BRCA1 (Ford et
al. 1994), and prostate cancer and pancreatic carcinoma,
for BRCA2 (Wooster et al. 1995 ). Most of the identified
mutations appear to be highly penetrant, conferring a
remarkably elevated lifetime cancer risk (Easton 1997).
The proportion of breast/ovarian cancer families whose
disease is attributable to BRCA1 or BRCA2 mutations
varies, depending on the population studied. Although
there seems to be a wide spectrum of different germ-line
mutations in most countries, some geographically or eth-
nically isolated populations, such as Icelanders and Ash-
kenazi Jews, have shown clusterings of specific muta-
tions (Szabo and King 1997; also see Breast Cancer
Information Core).
Population history explains much of the enrichment
of certain disease-related gene defects in Finland. The
concept of Finnish disease heritage currently includes
130 diseases that are more prevalent in Finland than in
other populations (de la Chapelle 1993). The majority
of these diseases are rare autosomal recessive disorders,
but founder mutations can also be seen in the more
common diseases, such as hereditary nonpolyposis colon
cancer (HNPCC) (Nystro¨m-Lahti et al. 1995). There-
fore, we were interested to see whether we could find
any mutational clustering in the BRCA1 and BRCA2
genes. Also, the phenotypic characteristics of the mu-
tation carriers were determined.
Eighty-eight families from the Oulu University Hos-
pital area (population 720,000), each with either at least
two cases of breast and/or ovarian cancer in first-degree
relatives or other characteristics of inherited suscepti-
bility (e.g., bilateral/multiple primary tumors or age at
diagnosis !40 years) were analyzed. Expression of breast
and ovarian cancer in these families is shown in table
1. Pedigree data were obtained from the probands by
means of a questionnaire and an interview. Permission
for genetic testing was requested during genetic coun-
seling. The study was approved by the Ethical Com-
mittee of the Oulu University Medical Faculty.
The protein-encoding and splice site–junction regions
of BRCA1 and BRCA2 were examined mainly by con-
formation-sensitive gel electrophoresis, the mutation-de-
tection sensitivity of which is estimated to be in the range
of 60%–95% (Ko¨rkko¨ et al. 1998). Exon 11 of BRCA1
and exons 10 and 11 of BRCA2 were screened by use
of protein-truncation test (Ha˚kansson et al. 1997). For
sequencing, we used Cyclist ExoPfu DNA Sequencing
Kit (Stratagene). The primer sets and PCR conditions
have been described elsewhere (Castilla et al. 1994;
Friedman et al. 1994, 1997; Couch et al. 1996). The
four microsatellite markers used to determine the dis-
ease-linked BRCA1 haplotypes were D17S846,
D17S855, D17S1322, and D17S1323 (Genome Data-
base).
Altogether, five distinct mutations were ob-
served—two in BRCA1 and three in BRCA2 (table 2).
The proportion of disease-related BRCA1 and BRCA2
mutations in the population studied was 12.5% (11/88).
The mutation prevalence of true high-risk families was
17% (6/36), and that for moderate-risk families was
10% (5/52), suggesting that a strong family history is
not the only parameter that can predict mutations; early
disease onset, tumor bilaterality, and multiple primary
tumors should also be taken into account. Cancer phe-
notypes are shown in table 2. BRCA1 mutations were
observed in 7% (6/88) of the studied kindreds: the
3745delT mutation leads to a premature protein-trans-
lation termination at codon 1209, and the ArG sub-
stitution at 4216-2nt generates an aberrant splice-ac-
ceptor recognition site. Both of these mutations were
present in three families. The proportion of BRCA2 mu-
tations was 6% (5/88): the 999del5 mutation leads
to translation termination at codon 273, and the
6503delTT mutation, which also is a frameshift muta-
tion, generates a stop codon 18 bp farther downstream.
Each of these two mutations was found in one family.
The ArG 9346-2nt splice-acceptor site mutation is pre-
dicted to result in the skipping of exon 24. Three families
were found to carry this mutation. In addition to the
disease-related mutations, other DNA alterations in the
coding regions were seen (table 3). Furthermore, several
polymorphisms were identified in the noncoding regions
of BRCA1 (in introns 6, 9, 17, 18, and 21) and BRCA2
(in exon 2 and introns 8, 24, and 25).
Interestingly, four of the mutations identified in our
study were found to be the same as those in another
Finnish study, by Vehmanen et al. (1997a, 1997b). Com-
bined data show the presence of the BRCA1 exon 11
3745delT mutation in six families, the BRCA1 exon 12
4216-2ntArG mutation in five families, the BRCA2
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Table 3
Polymorphisms and Unknown and Silent Variants Occurring in
Exonic Regions
Gene and Exon Alteration Effect Type (No. of Cases)a
BRCA1:
9 C710T CysrCys S (2)
11 C3832T ProrLeu UV (1)
13 T4427C SerrSer P (41)
15 G4654T SerrIle UV (1)
16 A4956G SerrGly P (27)
16 T5002C MetrThr UV (3)
16 T5074C MetrThr UV (1)
16 G5075A MetrIle P (3)
BRCA2:
25 T9639G ThrrThr S (1)
27 A10462G IlerVal UV (3)
a S  silent variant; UV  unknown variant; and P 
polymorphism.
Table 2
Mutations and Cancers in BRCA1 and BRCA2 Families
Family Gene Exon Mutation
Breast/Ovarian Cancer(s) in 1st- and 2d-
Degree Relatives (Age [years] at
Diagnosis)a Other Cancers (No. of Cases)a
014 BRCA1 11 3745delT Ov (46, 47, 50, 70b) Kid (1)
016 BRCA1 11 3745delT Br (47, u) Col (1), End (1), Lip (2), Liv (1)
062 BRCA1 11 3745delT Ov (44, 50) )
015 BRCA1 12 4216-2ntArG Br (28, 51, u), Ov (u) Bt (1), Liv (1)
017 BRCA1 12 4216-2ntArG Br (29,c 36, 42, 52, u), Ov (u), BrOv (52) Bt (1), Leu (1), Liv (1), Sto (1), Tes (1), Ton (1)
113 BRCA1 12 4216-2ntArG Br (62, u) Col (1), Cx (1), Lu (1), Sto (1)
034 BRCA2 9 999delTCAAA Bil Br (68/68d) Bo (1), Col (1), End (1), Lu (1), Sar (1)
028 BRCA2 11 6503delTT Br (77), Ov (64, u) End (2), Lu (1)
002 BRCA2 24 9346-2ntArG Br (45, 47, 48, u), Bil Br (62/64) Csu (3), Liv (3), Pro (1), Sto (1), Thy (1)
005 BRCA2 24 9346-2ntArG Br (37, 38, 46, 68) Csu (1), Leu (1)
087 BRCA2 24 9346-2ntArG Br (39) Lu (1), Mel (1), Pan (1), Sto (2)
a Bas  basalioma; Bil Br  bilateral breast cancer; Bo  bone cancer; Br  breast cancer; Bt  brain cancer; Col  colon cancer; Csu 
cancer site unknown; Cx  cervical cancer; End  endometrial cancer; Kid  kidney cancer; Leu  leukemia; Lip  lip cancer; Liv  liver
cancer; Lu  lung cancer; Mel  melanoma; Ov  ovarian cancer; Pan  pancreatic cancer; Pro  prostate cancer; Sar  sarcoma; Sto 
stomach cancer; Tes  testicular cancer; Thy  thyroid cancer; Ton  cancer of the tongue; and u  age unknown. Mutation carrier status
is not defined for all individuals.
b Endometrial cancer also present.
c Liver cancer also present.
d Basalioma (at age 69 years) and colon cancer (at age 72 years) also present.
exon 9 999del5 mutation in eight families, and the
BRCA2 exon 24 9346-2ntArG mutation in eight fam-
ilies, providing evidence of at least four different founder
mutations in Finland. At present, the BRCA1 exon 12
and BRCA2 exon 24 splice-site mutations appear to be
unique to the Finnish population, but the BRCA1
3745delT and BRCA2 999del5mutations have also been
observed in Sweden (Zelada-Hedman et al. 1997) and
Iceland (Johannesdottir et al. 1996), respectively. The
ancestors of all three families with the BRCA1 3745delT
mutation have been traced back to the late 19th century
and the same rural area south of Oulu. Families 014
and 016 share the same disease-linked haplotype for four
BRCA1 markers, indicating a common origin of the mu-
tation (data not shown). Interestingly, both families have
relatives living in Stockholm, where the Swedish family
with the BRCA1 3745delT mutations resides. Although
extensive migration from Finland to Sweden has oc-
curred for many centuries, there is no indication that
the Swedish family is related to the Finnish families in
our study. It is quite peculiar that the BRCA2 999del5
mutation, which occurs frequently in Iceland, appears
to be a founder mutation in Finland also but, as yet, has
not been reported in other Nordic countries. BRCA2
6503delTT is the only mutation with no present recur-
rence in the Finnish population. However, several other
families with this mutation have been identified else-
where (see Breast Cancer Information Core), and it is
possible that this site represents a mutational hot spot.
The observed phenotype of one breast cancer and two
ovarian cancers in family 028 corresponds well to what
was expected, since the mutation is located within the
ovarian cancer cluster region. This family was negative
for a polymorphic stop codon, lys3326ter, which has
been detected in some individuals carrying the
6503delTT mutation (Gayther et al. 1997). Haplotype
and genealogical studies to determine the age and pos-
sible common ancestors of the mutations that are now
observed—and to elucidate their relationship to the same
mutations observed in other populations—have been
initiated.
The population history of Finland differs, in many
respects, from that of most countries. The coastal areas
were populated mainly during the 15th century, and it
was not until the 17th century that the vast inland
regions were gradually inhabited by a relatively small
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number of individuals. The presence of several regionally
occurring BRCA1 and BRCA2 founder mutations could
reflect this development, a situation similar to that for
HNPCC. For instance, the four BRCA1 and BRCA2
Finnish founder mutations are responsible for 91% of
the mutations in the families studied in Oulu but for
only 45% of the mutations observed in the Helsinki
study. None of the other 12 mutations identified in the
study of individuals from southern Finland (Vehmanen
et al. 1997a, 1997b) was seen in our material.
The clustering of mutations provides significant di-
agnostic advantages. In HNPCC, for example, two mu-
tations have been found to account for a majority (63%)
of the Finnish cases. It has therefore become important
to design simple PCR-based tests for rapid mutation de-
tection (Nystro¨m-Lahti et al. 1995). Since the BRCA1
and BRCA2 founder mutations are currently seen in
55% (27/49) of the Finnish mutation-positive kindreds,
it makes meaningful the development of similar diag-
nostic tests for breast and ovarian cancer.
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A Triplet Repeat on 17q Accounts for Most
Expansions Detected by the Repeat-
Expansion–Detection Technique
To the Editor:
Eight hereditary neurogenerative disorders have been
identified that result from expansions of CAG trinucle-
otide repeats (Gilles et al. 1997). Thus, there has been
great incentive to develop techniques to efficiently screen
for repeat sequences in specific patient populations. The
repeat-expansion detection (RED) is a widely used tech-
nique that screens for trinucleotide expansions without
a requirement of prior knowledge of the disease locus
(Schalling et al. 1993; Zander et al. 1997). The method
uses genomic human DNA as a template, specific-repeat
oligonucleotide primers, and a thermostable ligase to
generate oligomers of the primer. However, there are
limitations to the technique. Non–disease-related ex-
pansions occur frequently in the population, which com-
plicate the interpretation of disease-association studies.
For a repeat to be detected by the RED, it must stand
out in size, and smaller expansions causing disease can
be missed. Also, once an expanded repeat is found, there
is no information about chromosomal localization.
Other techniques for identifying trinucleotide expan-
sions have recently been developed (Sanpei et al. 1996;
Koob et al. 1998). The direct identification of repeat
expansion and cloning technique (DIRECT) was de-
signed to enable the localization and cloning of ex-
panded-repeat regions (Sanpei et al. 1996). By means of
the DIRECT technique, a novel, long, and unstable
CAG/CTG trinucleotide repeat (Dir I) was identified and
localized to chromosome 17q (Ikeuchi et al. 1998). This
repeat is highly polymorphic, ranging in size from 10 to
92 repeat copies (30–276 bp) in normal individuals
(Ikeuchi et al. 1998). Independently, a second group
identified this expanded repeat by cloning the gene frag-
ment from RED positive DNAs (Nakamoto et al. 1997).
DNA samples, obtained with informed consent from
psychiatric patients with childhood onset of disease,
were studied specifically to detect increased numbers of
triplet repeats by use of the RED technique (Burgess et
al. 1998). Since children and adolescents with psychi-
atric disorders appear to have functional brain abnor-
malities (McKenna et al. 1994), these patients are a val-
uable resource for such studies. Although expansions of
trinucleotide repeats have been associated with several
disorders affecting the brain and nervous system, their
involvement in the etiology of psychiatric disorders has
not been clearly demonstrated (Lindblad et al. 1995;
Morris et al. 1995; O’Donovan et al. 1995). Since ex-
panded repeats can be associated with genetic antici-
pation, patients with an early onset of disease are es-
pecially good candidates to evaluate.
The RED technique was used to identify trinucleotide
expansions in 227 individuals, including 36 patients di-
agnosed with childhood-onset schizophrenia (COS); 21
diagnosed with atypical psychosis, termed by us as “mul-
tidimensionally impaired” (MDI) (Kumra et al. 1998);
46 patients with attention-deficit hyperactivity disorder
(ADHD); 51 screened controls; and 73 relatives of pro-
bands. Patients were diagnosed according to standard
Diagnostic and Statistical Manual of Mental Disorders
definitions with standardized interviews as described
elsewhere (Gordon et al. 1994; Castellanos et al. 1996).
Diagnostic criteria for theMDI group has been discussed
elsewhere (Kumra et al. 1998). The RED analysis was
performed with a CTG10 oligonucleotide in the RED
reaction, producing a repeat-size representation at 30-
nucleotide intervals (Lindblad et al. 1996; Zander et al.
1997). The same samples were then analyzed for ex-
pansions of the polymorphic CAG/CTG Dir I trinucle-
otide repeat on chromosome 17q, by use of PCR con-
ditions as described elsewhere (Ikeuchi et al. 1998; see
fig. 1).
RED expansions of x180 nucleotides were detected
in a total of 99 (44%) of the 227 individuals screened,
with the distribution of RED scores shown in table 1.
When diagnoses were evaluated separately, RED scores
of x180 nucleotides were seen in 41% of COS patients
( ), 43% of MDI patients ( ), 43% ofn  36 n  21
ADHD patients ( ), and 29% of the controlsn  24
( ) (fig. 2A).n  51
In analyzing the CAG/CTG repeat on chromosome
17q, we scored the allele in each individual with the
largest repeat size. A total of 81 (36%) of the 227 in-
dividuals screened had a chromosome 17q Dir I repeat
expansion of 1150 bp. Interestingly, 80 of the 81 indi-
viduals with a repeat size of 1150 bp on chromosome
17q had RED scores of x180 nucleotides. Thus, the
RED technique appeared to detect this expansion reli-
ably. There was also a strong correlation between the
size of the Dir I expansion and the size of the expansion
detected by RED (table 1).
Dir I repeats in excess of 50 copies (150 bp) were
